Asano Masaki, Imai Shungo, Shimizu Yuri, Kizaki Hayato, Ito Yukiko, Tsuchiya Makoto, Kuriyama Ryoko, Yoshida Nao, Shimada Masanori, Sando Takanori, Ishijima Tomo, Hori Satoko
Division of Drug Informatics, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
harmo Co, Ltd, Tokyo, Japan.
J Med Internet Res. 2024 Apr 24;26:e54645. doi: 10.2196/54645.
Understanding patient preference regarding taking tablet or capsule formulations plays a pivotal role in treatment efficacy and adherence. Therefore, these preferences should be taken into account when designing formulations and prescriptions.
This study investigates the factors affecting patient preference in patients who have difficulties swallowing large tablets or capsules and aims to identify appropriate sizes for tablets and capsules.
A robust data set was developed based on a questionnaire survey conducted from December 1, 2022, to December 7, 2022, using the harmo smartphone app operated by harmo Co, Ltd. The data set included patient input regarding their tablet and capsule preferences, personal health records (including dispensing history), and drug formulation information (available from package inserts). Based on the medication formulation information, 6 indices were set for each of the tablets or capsules that were considered difficult to swallow owing to their large size and concomitant tablets or capsules (used as controls). Receiver operating characteristic (ROC) analysis was used to evaluate the performance of each index. The index demonstrating the highest area under the curve of the ROC was selected as the best index to determine the tablet or capsule size that leads to swallowing difficulties. From the generated ROCs, the point with the highest discriminative performance that maximized the Youden index was identified, and the optimal threshold for each index was calculated. Multivariate logistic regression analysis was performed to identify the risk factors contributing to difficulty in swallowing oversized tablets or capsules. Additionally, decision tree analysis was performed to estimate the combined risk from several factors, using risk factors that were significant in the multivariate logistic regression analysis.
This study analyzed 147 large tablets or capsules and 624 control tablets or capsules. The "long diameter + short diameter + thickness" index (with a 21.5 mm threshold) was identified as the best indicator for causing swallowing difficulties in patients. The multivariate logistic regression analysis (including 132 patients with swallowing difficulties and 1283 patients without) results identified the following contributory risk factors: aged <50 years (odds ratio [OR] 1.59, 95% CI 1.03-2.44), female (OR 2.54, 95% CI 1.70-3.78), dysphagia (OR 3.54, 95% CI 2.22-5.65), and taking large tablets or capsules (OR 9.74, 95% CI 5.19-18.29). The decision tree analysis results suggested an elevated risk of swallowing difficulties for patients with taking large tablets or capsules.
This study identified the most appropriate index and threshold for indicating that a given tablet or capsule size will cause swallowing difficulties, as well as the contributory risk factors. Although some sampling biases (eg, only including smartphone users) may exist, our results can guide the design of patient-friendly formulations and prescriptions, promoting better medication adherence.
了解患者对服用片剂或胶囊剂型的偏好对治疗效果和依从性起着关键作用。因此,在设计剂型和处方时应考虑这些偏好。
本研究调查影响吞咽大片剂或胶囊有困难的患者偏好的因素,旨在确定片剂和胶囊的合适尺寸。
基于2022年12月1日至2022年12月7日使用harmo有限公司运营的harmo智能手机应用程序进行的问卷调查,建立了一个强大的数据集。该数据集包括患者关于其片剂和胶囊偏好、个人健康记录(包括配药历史)以及药物剂型信息(可从药品说明书中获取)的输入。根据药物剂型信息,为每片因尺寸大而被认为难以吞咽的片剂或胶囊以及伴随的片剂或胶囊(用作对照)设置了6个指标。采用受试者工作特征(ROC)分析来评估每个指标的性能。选择ROC曲线下面积最大的指标作为确定导致吞咽困难的片剂或胶囊尺寸的最佳指标。从生成的ROC曲线中,确定具有最高判别性能且使约登指数最大化的点,并计算每个指标的最佳阈值。进行多变量逻辑回归分析以确定导致吞咽超大片剂或胶囊困难的危险因素。此外,使用多变量逻辑回归分析中有显著意义的危险因素进行决策树分析,以估计几个因素的综合风险。
本研究分析了147片大片剂或胶囊和624片对照片剂或胶囊。“长径+短径+厚度”指标(阈值为21.5毫米)被确定为导致患者吞咽困难的最佳指标。多变量逻辑回归分析(包括132名有吞咽困难的患者和1283名无吞咽困难的患者)结果确定了以下促成危险因素:年龄<50岁(比值比[OR]1.59,95%置信区间1.03 - 2.44)、女性(OR 2.54,95%置信区间1.70 - 3.78)、吞咽困难(OR 3.54,95%置信区间2.22 - 5.65)以及服用大片剂或胶囊(OR 9.74,95%置信区间5.19 - 18.29)。决策树分析结果表明服用大片剂或胶囊的患者吞咽困难风险升高。
本研究确定了表明给定片剂或胶囊尺寸会导致吞咽困难的最合适指标和阈值,以及促成危险因素。尽管可能存在一些抽样偏差(例如,仅包括智能手机用户),但我们的结果可为设计方便患者的剂型和处方提供指导,促进更好的药物依从性。